These risks are more fully described in the section titled “Risk Factors,” including the following:•We have a limited operating history, have never generated any revenues from drug sales and have incurred significant operating losses since inception.•We anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.•We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all.•We may be required to make significant payments in connection with our licenses of OV101 from Lundbeck and OV935 from Takeda.•Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug
have favorable results in planned or future studies or trials, or may not receive regulatory approval.•Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of
candidates or technologies;•initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;•seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;•establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;•develop, maintain, expand and protect our intellectual property portfolio;•implement operational, financial and management systems; and•attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.In addition, because of the numerous risks and uncertainties
to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.10Table of ContentsWe have a limited operating history and have never generated any revenue from drug
such arrangements;•our ability to obtain and maintain orphan drug exclusivity for any of our current and future drug candidates for which we obtain regulatory approval;•maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets andknow-how;•avoiding and defending against third-party interference or infringement claims; and•securing appropriate pricing in the United States, the European Union and other countries.We expect our financial condition and operating results to
arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us.If we are unable to raise additional capital when needed, we
If we are unable to successfully commercialize our current and future drug candidates, we may not be able to generate sufficient revenue to continue our business.Because the results of preclinical studies or earlier
The risks associated with acquiring orin-licensingcurrent or future drug candidates could result in delays in the commencement or completion of our preclinical studies and clinical trials, if ever, and our ability to generate revenues from our
result in increased time and expense to train investigators and open clinical sites.Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and
impact on our operational results and financial condition.If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.A key element of our strategy is to
our business, prospects, financial condition and results of operations.We may be required to relinquish important rights to and control over the development and commercialization of our drug candidates to any future collaborators.Our current and future collaborations could subject us to a
existing and potential competitors, our business and financial condition may be harmed.As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our drug candidates.
and our business, financial condition, results of operations and prospects could be harmed.If we seek approval to commercialize our current or future drug candidates outside of the United States, in particular in the European Union and Israel, a variety of risks associated with
international operations could harm our business.If we seek approval of our current or future drug candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:•different regulatory requirements for approval of therapies in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation, or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;25Table of Contents•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing
may not be able to successfully commercialize our current and any future drug candidates that we develop.Healthcare legislative reform measures may have a negative impact on our business and results of operations.In the United States and some foreign jurisdictions, there